Contact Us

Your Name (required)

Your Email (required)

Subject

Your Message

A note to patients: Vaxil frequently receives requests from patients seeking our experimental drugs. Please keep in mind that Vaxil’s products remain unproven, investigational and in clinical trial phases. Unfortunately, Vaxil therefore does not have the ability to sell or give away any of its drugs. Furthermore, at the time, Vaxil does not have any ongoing clinical trials recruiting patients. Any patient cases sent to Vaxil can be kept on file should an applicable clinical trial be approved down the line, but there can be no assurance of this occurring. We are doing our best to advance our pipeline of drugs, but it is a lengthy process and Vaxil adheres closely to drug development regulations.

Wishing you the very best,

The Vaxil Team



VAXIL – Creating the ideal immunotherapy

Inducing a Broad

Response

Learn More

universally

Applicable

Learn More

Overcoming

Cancer Resistance

Learn More

Harnessing Potent

Immune Response

Learn More

Tumor

Specific

Learn More

Expression on

Cancer Stem Cells

Learn More

neo-antigen

acting

Learn More

First Ever SP-Specific

Antibody Platform

Learn More

Vaxil’s Lead Products and Orphan Drug Status

Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is ​its ImMucin™ ​lead immunotherapy product.